|
|
|
|
|
|
|
|
|
|
|
08.10.25 - 15:03
|
SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet (GlobeNewswire EN)
|
|
|
COMMACK, NY, Oct. 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that on October 3, 2025, it entered into an agreement (the “Agreement”) with Arena Finance Markets, LP and Arena Special Opportunities III LP (together, the “Arena Investors”) to fully discharge all outstanding balances on the secured convertible debentures (the “Debentures”) previously issued to the Arena Investors by the Company....
|
|
|
|
|
|
|
|
|
14.08.25 - 15:03
|
Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock (GlobeNewswire EN)
|
|
|
Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (Nasdaq: SCNX) (“Scienture” or the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 3,225,000 shares of common stock at an offering price of $1.20 per share, in a registered direct offering. The gross proceeds for the offering are expected to be approximately $3.9 million before deducting placement agent fees and other offering expenses. This offering is expected to close on August 15, 2025, subject to customary closing conditions....
|
|
|
13.08.25 - 14:09
|
SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones. (GlobeNewswire EN)
|
|
|
COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the shipment of launch quantities of Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL to its 3PL/Distribution Center for the intended commercial launch of the product. This shipment marks a major milestone accomplishment for Scienture, which has agreements in place for the distribution of the product through wholesalers and has received its first order for shipment in August 2025....
|
|
|
|
|
|
|
24.07.25 - 23:15
|
Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding (GlobeNewswire EN)
|
|
|
Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that its board of directors has approved a bridge funding raise of up to an aggregate amount of $3 million, of which it has secured approximately $1.2 million, through the issuance of shares of the Company's common stock to institutional or accredited investors....
|
|
|
|
|
16.07.25 - 14:18
|
Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire EN)
|
|
|
Commack, NY, July 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has received a notification letter from The Nasdaq Stock Market (“Nasdaq”) stating that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of the Company's common stock has been at $1.00 per share or greater for the previous ten consecutive business days....
|
|
|
17.06.25 - 14:09
|
Scienture Holdings Announces Cancelation of ELOC (GlobeNewswire EN)
|
|
|
TAMPA, FL, June 17, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, announced it has terminated its Equity Line of Credit (“ELOC”) facility effective as of May 22, 2025....
|
|
|
|
|
22.05.25 - 14:09
|
SCIENTURE Announces Executive Leadership Transition (GlobeNewswire EN)
|
|
|
TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani....
|
|
|
19.05.25 - 14:06
|
SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL. (GlobeNewswire EN)
|
|
|
TAMPA, FL, May 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that the U.S. Food and Drug Administration (FDA) has listed U.S. Patent Nos. 11890273 (the '273 patent) and 12156869 (the '869 patent), each with an expiration date of October 2041, in its Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) for Arbli™, (losartan potassium) Oral Suspension, 10mg/mL, approved under New Drug Application (NDA# N218772)....
|
|
|
22.04.25 - 14:09
|
SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. (GlobeNewswire EN)
|
|
|
TAMPA, FL, April 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the initiation of supply chain activities by its wholly owned subsidiary Scienture, LLC to manufacture launch quantities of ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL for the intended commercial launch of the product in July 2025. Scirenture, LLC's contract manufacturing partner, Saptalis Pharmaceuticals, LLC for ArbliTM has indicated to Scienture that Saptalis has the materials and capabilities to produce the batches and supply product inventory in time for the target commercial launch. In addition, Scienture, LLC has also entered into agreements with strategic partners for warehousing and distributing the product to the ...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
